Warm Autoimmune Hemolytic Anemia Clinical Trial
Official title:
Nipocalimab Post-trial Access in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) Who Are Experiencing Clinical Benefit After Complete 28-Weeks Open-label Extension in MOM-M281-006
NCT number | NCT05221619 |
Other study ID # | CR109152 |
Secondary ID | 80202135WHA4001 |
Status | Temporarily not available |
Phase | |
First received | |
Last updated |
Verified date | January 2024 |
Source | Janssen Research & Development, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Expanded Access |
The purpose of this post-trial access (PTA) program is to provide nipocalimab for the treatment of participants with Warm Autoimmune Hemolytic Anemia (wAIHA) who are experiencing clinical benefit after completing 28-weeks open-label extension in MOM-M281-006 (NCT04119050) study.
Status | Temporarily not available |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Participants demonstrate clinical benefit (improvement of hemoglobin from baseline) at the Week 28 assessment in the open-label extension of the MOM-M281-006 (NCT04119050) study - Participants does not have co-morbidities that would alter the risk-benefit of nipocalimab administration (determined by treating physician) - Participants completed treatment in the 28-week open-label extension of the MOM-M281-006 (NCT04119050) study without receiving rescue treatment or discontinuation of the study prior to Week 28 visit Exclusion Criteria: - Participants have a serious or clinically significant infection (example: pneumonia, biliary tract infection, diverticulitis, Clostridioides difficile infection) requiring parenteral anti-infectives and/or hospitalization - Participants have a chronic infection (example: bronchiectasis, chronic osteomyelitis, chronic pyelonephritis) or require chronic treatment with anti-infectives (example: antibiotics, antivirals) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Janssen Research & Development, LLC |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05786573 -
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
|
Phase 3 | |
Withdrawn |
NCT03965624 -
Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
|
Phase 2 | |
Recruiting |
NCT05922839 -
Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA
|
Phase 2 | |
Completed |
NCT01181154 -
Rituximab in Auto-Immune Hemolytic Anemia
|
Phase 3 | |
Recruiting |
NCT05925023 -
Sirolimus in the Treatment of Refractory/Relapsed wAIHA
|
Phase 2 | |
Recruiting |
NCT05757570 -
An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04256148 -
ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
|
Phase 2 | |
Terminated |
NCT03075878 -
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04956276 -
Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
|
Phase 2 | |
Completed |
NCT03226678 -
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
|
Phase 2 | |
Recruiting |
NCT04119050 -
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
|
Phase 2/Phase 3 | |
Terminated |
NCT04253236 -
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
|
Phase 2 |